Form 8-K Mast Therapeutics, Inc. For: Oct 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq slides over 1% as Alphabet results revive AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Mast Therapeutics, Inc. (MSTX) Reports In-Line Q3 Loss
October 31, 2014 9:30 AM EDTMast Therapeutics, Inc. (NYSE: MSTX) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06).
For earnings history and earnings-related data on Mast Therapeutics, Inc. (MSTX) click here.
... More


